The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
for
Autoimmune Encephalitis, Encephalitis
Location: Boston MA, New Haven CT, Brooklyn NY, New York NY,
Sponsor: University of Utah
Sex: All
Age: 12+
Code: NCT04372615
Phase2, Recruiting
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
for
Long Term Follow-up
Location: Hillsborough NJ, San Diego CA
Sponsor: Arbutus Biopharma Corporation
Sex: All
Age: 20 - 70
Code: NCT06277037
Recruiting
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
for
Melanoma
Location: Durham NC
Sponsor: Duke University
Sex: All
Age: 18+
Code: NCT05077137
Phase1, Recruiting
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma